ArticleArthritis care & research2026
Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease Cohort.
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Type I Interferon and Still Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Reliability and Construct Validity of the Physician's Global Assessment of Lung Disease in Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease.ACR open rheumatology · 2026Article
- Decoding pulmonary risk in childhood-onset still's disease: immunogenetic determinants and implications for risk stratification.Respiratory research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
objectivesChronic lung disease is a potentially life-threatening complication of systemic juvenile idiopathic arthritis (SJIA-LD). However, its natural history, etiology, and effective management are unclear. We aimed to describe the baseline characteristics and biomarker profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry SJIA-LD cohort.
methodsBaseline data from all CARRA Registry patients with SJIA and those with SJIA-LD were included and analyzed. Lung disease-specific data were obtained using a standardized case report form through REDCap Cloud. Plasma biomarker profiles were determined using a custom Luminex panel.
resultsA total of 37 patients with SJIA-LD from 16 CARRA sites were identified and compared to all 928 patients with SJIA without known LD in the CARRA Registry. Patients with SJIA-LD were significantly younger at disease onset and were more likely to be of Asian descent. A higher medication burden was also found. Patients with SJIA-LD had higher levels of multiple lung injury biomarkers, cytokines, and chemokines compared to patients with both active and inactive SJIA without LD and healthy controls. Cluster analysis proposed three groups of SJIA-LD patients with distinct biomarker patterns reflecting differences in proinflammatory cytokines, type II chemokines, and markers of macrophage activation syndrome (MAS).
conclusionsThe CARRA SJIA-LD Cohort exhibits distinct clinical features, higher medication burden, frequent MAS, and plasma biomarker patterns specific to SJIA-LD compared to patients with SJIA without LD. A study is ongoing to assess more detailed clinical features, disease progression, patient-reported outcomes, and associated immune biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.